Table 1.
MICs of 20 antibiotics for 39 Cupriavidus clinical strains, including two type strains, determined by the broth microdilution method
| Bacteria (n) | Antibiotic | MIC (mg/L) |
Percentage susceptible (breakpoint, mg/L) | Percentage resistant (breakpoint, mg/L) | |
|---|---|---|---|---|---|
| MIC50 | MIC90 | ||||
| Cupriavidus spp., all isolates (39) | amikacin | 64 | 512 | 23 (≤8) | 72 (>16) |
| amoxicillin | 512 | >512 | 5 (≤2) | 90 (>8) | |
| amoxicillin/clavulanate | 256 | >512 | 8 (≤2) | 87 (>8) | |
| aztreonam | 32 | 256 | 0 (≤4) | 97 (>8) | |
| cefepime | 1 | 4 | 95 (≤4) | 0 (>8) | |
| cefotaxime | 1 | 2 | 82 (≤1) | 8 (>2) | |
| ceftazidime | 16 | 32 | 23 (≤4) | 54 (>8) | |
| ceftazidime/avibactam | 8 | 32 | 69 (≤8) | 31 (>8) | |
| ceftolozane/tazobactam | 2 | 8 | 90 (≤4) | 10 (>4) | |
| ceftriaxone | 1 | 4 | 74 (≤1) | 10 (>2) | |
| ciprofloxacin | 0.125 | 1 | 74 (≤0.25) | 18 (>0.5) | |
| colistin | 2 | 16 | 56 (≤2) | 44 (>2) | |
| co-trimoxazole | 1 | 128 | 62 (≤2) | 38 (>2) | |
| imipenem | 2 | 8 | 69 (≤2) | 21 (>4) | |
| levofloxacin | 0.25 | 2 | 79 (≤0.5) | 18 (>1) | |
| meropenem | 32 | 64 | 8 (≤2) | 74 (>8) | |
| minocycline | ≤0.06 | 0.5 | 100 (≤4) | 0 (>8) | |
| piperacillin/tazobactam | 8 | 128 | 46 (≤4) | 26 (>16) | |
| temocillin | 32 | 512 | 31 (≤16) | 69 (>16) | |
| tobramycin | 256 | >256 | 21 (≤4) | 79 (>4) | |
| C. respiraculi (18) | amikacin | 128 | 512 | 6 (≤8) | 89 (>16) |
| amoxicillin | 512 | >512 | 0 (≤2) | 100 (>8) | |
| amoxicillin/clavulanate | 512 | >512 | 0 (≤2) | 100 (>8) | |
| aztreonam | 32 | 32 | 0 (≤4) | 100 (>8) | |
| cefepime | 2 | 4 | 89 (≤4) | 0 (>8) | |
| cefotaxime | 1 | 2 | 78 (≤1) | 11 (>2) | |
| ceftazidime | 16 | 16 | 6 (≤4) | 61 (>8) | |
| ceftazidime/avibactam | 8 | 16 | 72 (≤8) | 28 (>8) | |
| ceftolozane/tazobactam | 2 | 4 | 94 (≤4) | 6 (>4) | |
| ceftriaxone | 1 | 4 | 67 (≤1) | 17 (>2) | |
| ciprofloxacin | 0.06 | >16 | 83 (≤0.25) | 17 (>0.5) | |
| colistin | 1 | 2 | 94 (≤2) | 6 (>2) | |
| co-trimoxazole | 0.5 | 128 | 78 (≤2) | 22 (>2) | |
| imipenem | 2 | 8 | 61 (≤2) | 22 (>4) | |
| levofloxacin | 0.125 | 16 | 83 (≤0.5) | 17 (>1) | |
| meropenem | 64 | 64 | 0 (≤2) | 83 (>8) | |
| minocycline | ≤0.06 | 0.125 | 100 (≤4) | 0 (>8) | |
| piperacillin/tazobactam | 8 | 16 | 39 (≤4) | 11 (>16) | |
| temocillin | 32 | 32 | 50 (≤16) | 50 (>16) | |
| tobramycin | >256 | >256 | 6 (≤4) | 94 (>4) | |
| C. pauculus (5) and C. metallidurans (4) | amikacin | 8 | 128 | 56 (≤8) | 33 (>16) |
| amoxicillin | 256 | 512 | 0 (≤2) | 78 (>8) | |
| amoxicillin/clavulanate | 128 | 256 | 11 (≤2) | 78 (>8) | |
| aztreonam | 256 | 512 | 0 (≤4) | 100 (>8) | |
| cefepime | 0.5 | 1 | 100 (≤4) | 0 (>8) | |
| cefotaxime | 1 | 2 | 67 (≤1) | 11 (>2) | |
| ceftazidime | 8 | 16 | 33 (≤4) | 44 (>8) | |
| ceftazidime/avibactam | 8 | 16 | 78 (≤8) | 22 (>8) | |
| ceftolozane/tazobactam | 2 | 4 | 100 (≤4) | 0 (>4) | |
| ceftriaxone | 1 | 2 | 78 (≤1) | 0 (>2) | |
| ciprofloxacin | 0.5 | 1 | 44 (≤0.25) | 44 (>0.5) | |
| colistin | 16 | 32 | 0 (≤2) | 100 (>2) | |
| co-trimoxazole | 16 | 256 | 22 (≤2) | 78 (>2) | |
| imipenem | 0.25 | 2 | 100 (≤2) | 0 (>4) | |
| levofloxacin | 1 | 2 | 44 (≤0.5) | 44 (>1) | |
| meropenem | 16 | 64 | 11 (≤2) | 67 (>8) | |
| minocycline | 0.25 | 0.5 | 100 (≤4) | 0 (>8) | |
| piperacillin/tazobactam | 2 | 32 | 67 (≤4) | 22 (>16) | |
| temocillin | 256 | 512 | 0 (≤16) | 100 (>16) | |
| tobramycin | 64 | 128 | 44 (≤4) | 56 (>4) | |
| C. gilardii (6) | amikacin | 64 | 128 | 0 (≤8) | 100 (>16) |
| amoxicillin | >512 | >512 | 0 (≤2) | 100 (>8) | |
| amoxicillin/clavulanate | >512 | >512 | 0 (≤2) | 100 (>8) | |
| aztreonam | 128 | 128 | 0 (≤4) | 100 (>8) | |
| cefepime | 4 | 4 | 100 (≤4) | 0 (>8) | |
| cefotaxime | 1 | 1 | 100 (≤1) | 0 (>2) | |
| ceftazidime | 32 | 32 | 17 (≤4) | 83 (>8) | |
| ceftazidime/avibactam | 32 | 32 | 33 (≤8) | 67 (>8) | |
| ceftolozane/tazobactam | 8 | 16 | 50 (≤4) | 50 (>4) | |
| ceftriaxone | 1 | 2 | 67 (≤1) | 17 (>2) | |
| ciprofloxacin | 0.25 | 0.25 | 83 (≤0.25) | 0 (>0.5) | |
| colistin | 1 | 4 | 67 (≤2) | 33 (>2) | |
| co-trimoxazole | 1 | 1 | 83 (≤2) | 17 (>2) | |
| imipenem | 8 | 8 | 17 (≤2) | 67 (>4) | |
| levofloxacin | 0.25 | 0.25 | 100 (≤0.5) | 0 (>1) | |
| meropenem | 64 | 64 | 0 (≤2) | 100 (>8) | |
| minocycline | 0.125 | 0.125 | 100 (≤4) | 0 (>8) | |
| piperacillin/tazobactam | 128 | 128 | 0 (≤4) | 83 (>16) | |
| temocillin | 512 | >512 | 0 (≤16) | 100 (>16) | |
| tobramycin | 256 | >256 | 0 (≤4) | 100 (>4) | |
| C. basilensis (1), C. necator (2), C. taiwanensis (2) and Cupriavidus sp. (1) | amikacin | 32 | 64 | 50 (≤8) | 50 (>16) |
| amoxicillin | 32 | 256 | 33 (≤2) | 67 (>8) | |
| amoxicillin/clavulanate | 16 | 64 | 33 (≤2) | 50 (>8) | |
| aztreonam | 64 | 128 | 0 (≤4) | 83 (>8) | |
| cefepime | ≤0.25 | ≤0.25 | 100 (≤4) | 0 (>8) | |
| cefotaxime | 0.5 | 1 | 100 (≤1) | 0 (>2) | |
| ceftazidime | 4 | 8 | 67 (≤4) | 17 (>8) | |
| ceftazidime/avibactam | 4 | 8 | 83 (≤8) | 17 (>8) | |
| ceftolozane/tazobactam | 1 | 1 | 100 (≤4) | 0 (>4) | |
| ceftriaxone | 0.25 | 1 | 100 (≤1) | 0 (>2) | |
| ciprofloxacin | 0.125 | 0.25 | 83 (≤0.25) | 0 (>0.5) | |
| colistin | 16 | 16 | 17 (≤2) | 83 (>2) | |
| co-trimoxazole | 16 | 64 | 50 (≤2) | 50 (>2) | |
| imipenem | 0.25 | 2 | 100 (≤2) | 0 (>4) | |
| levofloxacin | 0.125 | 0.25 | 100 (≤0.5) | 0 (>1) | |
| meropenem | 8 | 16 | 33 (≤2) | 33 (>8) | |
| minocycline | ≤0.06 | 0.5 | 100 (≤4) | 0 (>8) | |
| piperacillin/tazobactam | 1 | 4 | 83 (≤4) | 17 (>16) | |
| temocillin | 128 | 512 | 50 (≤16) | 50 (>16) | |
| tobramycin | 64 | 64 | 50 (≤4) | 50 (>4) | |